Sandoz Gets U.S. Distribution Rights for Two Hospital-Injectable Medicines
March 23 2020 - 5:07PM
Dow Jones News
By Stephen Nakrosis
Sandoz on Monday said it has acquired the U.S. distribution
rights to a pair of hospital-injectable medicines "to reinforce the
company's strategy to grow its injectables portfolio and overall
offerings in the hospital setting."
Sandoz, a division of Novartis, said it acquired the U.S.
distribution rights to daptomycin 500mg injection and fosaprepitant
150mg for injection from BE Pharmaceuticals AG.
Daptomycin is used in the treatment of certain infections and is
the generic version of Cubicin. Fosaprepitant, the generic prodrug
of Emend, is used to prevent nausea and vomiting in chemotherapy
patients, the company said.
Sandoz President Carol Lynch said, "Our ambition is to make
Sandoz the world's leading and most valued generics company. To
realize that ambition in the U.S. market, we are focusing on
specific segments such as hospitals and oncology clinics with
generic and branded generic injectables, where we can do the most
to pioneer access for patients."
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
March 23, 2020 16:52 ET (20:52 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024
